Tests two new targeted drugs in adults with active rheumatoid arthritis
Tests lutikizumab and ravagalimab, alone or together, in adults with active rheumatoid arthritis.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
Key facts
- Where
- Albuquerque, Austin, Avon Park, Beverly Hills, Carrollton, Charlotte, Chicago, Chula Vista, Clearwater, Corpus Christi, Duncansville, Fort Collins, Frisco, Grand Blanc, Great Neck, Greenacres City, Hialeah, Hollywood, Houston, Huntington Beach, Jackson, Jacksonville, Jonesboro, Katy, Lake Charles, Libertyville, Margate, Mesquite, Middleburg Heights, Orland Park, Orlando, Palm Beach Gardens, Peoria, Plano, Red Oak, Skokie, Sugar Land, Summerville, Tampa, Thousand Oaks, Tomball, Torrance, Upland, West Long Branch, and Willowbrook, United StatesSee the 49 sites
- Phase
- Phase 2
Where in United States
- Albuquerque Center For Rheumatology /ID# 272301Albuquerque, United StatesTaking people
- Tekton Research - West Gate /ID# 272270Austin, United StatesTaking people
- Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 272298Avon Park, United StatesTaking people
- Private Practice - Dr. David S. Hallegua /ID# 277608Beverly Hills, United StatesTaking people
- Trinity Universal Research Associates - Carrollton /ID# 272577Carrollton, United StatesTaking people
- DJL Clinical Research - Charlotte /ID# 272387Charlotte, United StatesTaking people
- Joint And Muscle Research Institute /ID# 277290Charlotte, United StatesTaking people
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 275422Chicago, United StatesTaking people
- Advanced Clinical Research Center, LLC dba TriWest Research Associates /ID# 277826Chula Vista, United StatesTaking people
- Clinical Research Of West Florida - Phase I Unit /ID# 272428Clearwater, United StatesTaking people
- Arthritis Care Of Texas /ID# 277961Corpus Christi, United StatesTaking people
- Altoona Center For Clinical Research /ID# 272479Duncansville, United StatesTaking people
- Tekton Research - Fort Collins - East Harmony Road /ID# 272472Fort Collins, United StatesTaking people
- Arthritis and Rheumatology Research Institute - Frisco /ID# 272299Frisco, United StatesTaking people
- AA Medical Research Center - Grand Blanc /ID# 272496Grand Blanc, United StatesTaking people
- Northwell Health Physician Partners Rheumatology At Great Neck /ID# 275621Great Neck, United StatesTaking people
- Finlay Medical Research - Greenacres /ID# 281654Greenacres City, United StatesTaking people
- Neoclinical Research - Hialeah /ID# 272070Hialeah, United StatesTaking people
- South Florida Rheumatology /ID# 278339Hollywood, United StatesTaking people
- Accurate Clinical Research - Houston /ID# 272271Houston, United StatesTaking people
- Care & Cure Clinic /ID# 281684Houston, United StatesTaking people
- Private Practice - Dr. Laila A. Hassan /ID# 272297Houston, United StatesTaking people
- Newport Huntington Medical Group /ID# 272439Huntington Beach, United StatesTaking people
- West Tennessee Research Institute /ID# 272453Jackson, United StatesTaking people
- Swati Shah, MD Rheumatology /ID# 273624Jacksonville, United StatesTaking people
- Arthritis And Rheumatism Associates (Ara) - Jonesboro /ID# 272896Jonesboro, United StatesTaking people
- Biopharma Informatic /ID# 279189Katy, United StatesTaking people
- Accurate Clinical Research (SMO/Network/Consortium) /ID# 272650Lake Charles, United StatesTaking people
- Deerbrook Medical Associates /ID# 273439Libertyville, United StatesTaking people
- Life Clinical Trials - Colonial Drive - Margate /ID# 272589Margate, United StatesTaking people
- Southwest Rheumatology Research /ID# 272268Mesquite, United StatesTaking people
- Paramount Medical Research and Consulting /ID# 272474Middleburg Heights, United StatesTaking people
- Advanced Quality Medical Research /ID# 277824Orland Park, United StatesTaking people
- HMD Research LLC /ID# 272432Orlando, United StatesTaking people
- Vitalia Research /ID# 272478Palm Beach Gardens, United StatesTaking people
- Sun Valley Arthritis Center /ID# 278331Peoria, United StatesTaking people
- Texas Rheumatology Research Institute /ID# 278010Plano, United StatesTaking people
- Epic Medical Research /ID# 272656Red Oak, United StatesTaking people
- Arnold Arthritis & Rheumatology /ID# 278354Skokie, United StatesTaking people
- Fort Bend Rheumatology Associates /ID# 280761Sugar Land, United StatesTaking people
- Low Country Rheumatology /ID# 277607Summerville, United StatesTaking people
- Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 272755Tampa, United StatesTaking people
- Cohen Medical Centers /ID# 278341Thousand Oaks, United StatesTaking people
- DM Clinical Research - Tomball /ID# 272452Tomball, United StatesTaking people
- Dm Clinical Research -Tomball Rch /ID# 281787Tomball, United StatesTaking people
- The Lundquist Institute /ID# 272481Torrance, United StatesTaking people
- Inland Rheumatology and Osteoporosis Medical Group /ID# 272449Upland, United StatesTaking people
- Sahni Rheumatology & Therapy /ID# 278352West Long Branch, United StatesTaking people
- Willow Rheumatology and Wellness /ID# 272691Willowbrook, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06972446EU 2025-520721-21-00
- Record updated
- 8 October 2026
- Original description
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).Read full original descriptionShow less
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies for the treatment of moderately to severely active Rheumatoid Arthritis (RA).
This study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion: At any time prior to the Screening Visit, participant must have been treated for > or = 3 months with at least 1 b/tsDMARD therapy but continued to exhibit active RA, or had to discontinue due to intolerability or toxicity, irrespective of treatment duration. The maximum cap for prior use of b/tsDMARD is 2; Participant must be on a stable dose of methotrexate (MTX).
Exclusion: Participant is taking nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen/paracetamol, low-potency opioids (tramadol, codeine, hydrocodone, alone or in combination with acetaminophen), oral corticosteroids (equivalent to ≤ 10 mg/day of prednisone), or inhaled corticosteroids for stable medical conditions unless they have been on stable doses for ≥ 1 week prior to Baseline Visit; History of any arthritis with onset prior to age 17 years or current diagnosis of inflammatory joint disease other than rheumatoid arthritis.